Pfizer Loses Bid for Supreme Court Review of Copay Ruling (1)

The US Supreme Court won’t review a ruling that blocked Pfizer Inc. from using a program to help middle-income Medicare beneficiaries pay for the company’s expensive heart disease drug.

Justices on Monday denied Pfizer’s request to reconsider a decision by the US Court of Appeals for the Second Circuit, which ruled that the company’s proposal to cover copays for tafamidis would limit Congress’s goal to control Medicare costs, as well as violate the Anti-Kickback Statute. The statute prohibits efforts to reward business referrals in federal health programs. The Second Circuit ruling upheld a 2020 Department of Health and Human Services ...